Project description:The current study analyzed the altered expression profiles of genes that are responsible for fluvastatin-induced breast cancer cell death in MCF-7 cells (ER+ve luminal breast cancer cells). Some of these altered gene expressions were further inter connceted to various pathways which may eventually be recognised as drug targets/ biomarkers in statin-sensitve breast cancer patients. To understand the differential gene expression profile in fluvastatin treated (24 h) malignant breast cancer cells with untreated malignant breast cancer cells.
Project description:The current study analyzed the altered expression profiles of genes that are responsible for fluvastatin-induced breast cancer cell death in MDA-MB-231 cells (ER-ve basal breast cancer cells). Some of these altered gene expressions were further inter connceted to various pathways which may eventually be recognised as drug targets/ biomarkers in statin-sensitve breast cancer patients. To understand the differential gene expression profile in fluvastatin treated (24 h) malignant breast cancer cells with untreated malignant breast cancer cells.
Project description:The current study analyzed the altered expression profiles of genes that are responsible for fluvastatin-induced breast cancer cell death in MCF-7 cells (ER+ve luminal breast cancer cells). Some of these altered gene expressions were further inter connceted to various pathways which may eventually be recognised as drug targets/ biomarkers in statin-sensitve breast cancer patients.
Project description:The current study analyzed the metadherin (MTDH)-mediated altered gene expression profiles in ER positive MCF-7 cells. Some of these altered gene expressions were further inter connected to various pathways which may eventually be recognized as drug targets or biomarkers in those breast cancers where MTDH plays a role in cancer progression/metastasis. To understand the global differential gene expression profile in MTDH-wild type and a newly identified MTDH-isoform knock down in malignant breast cancer cells. This data was compared to untreated breast cancer cells.
Project description:Microarray analysis of microRNAs differences between MCF-7 and MCF-7/ADR cells.Sample 1- Human breast cancer cell MCF-7,which exibits ER and PR expression, belongs to non-triple negative breast cancer cell with epithelial morphology and character.Sample 2-human breast cancer cell MCF-7/ADR,derived from MCF-7 and cultured with 1 ug/ml adriamycin for at least one year and pocesses adriamycin-resistance with mesenchymal morphology and character. We used microarrays to detail the global programme of microRNA expression between two distinct classes of breast cancer cells.
Project description:Transcriptional profiling of human MCF-7 breast cancer cells comparing MCF-7 cells treated with control medium (DMEM/F12 + 0,5% BSA) with MCF-7 cells treated with conditioned medium of cancer-associated adipose tissue (CMCAAT) obtained from 2 breast cancer patients. Goal was to determine the effects of CMCAAT treatment on global MCF-7 gene expression.
Project description:Breast cancer (BC) is the most prevalent and lethal tumor among women worldwide.
Although the antitumor effects of melatonin are well documented, its precise molecular
mechanisms in specific breast cancer subtypes remain unclear. This dataset provides
proteomic data from total protein extracts of two breast cancer cell lines [MCF-7
(ER+and PR+) and MDA-MB-468 (triple negative) treated with melatonin. The aim of
the study was to identify melatonin-induced changes in global protein expression and to
assess its potential as a therapeutic modulator in hormone-responsive and triple-negative
breast cancer.
Project description:We studied genes, that are differentially expressed between malignant and normal breast tissue, to find weak spots for anti-cancer therapy development. RNA sequencing of three cell lines was performed: MCF-7 (epithelial breast cancer cell line), BCC (primary breast tumour cell line) and MCF-10A (epithelial breast cell line).
